Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monosialotetrahexosylganglioside for Oxaliplatin Induced Neurotoxicity
NCT02486198Phase 3Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2015
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of monosialotetrahexosylganglioside in neurotoxicity, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started May 2015; status: completed.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
neurotoxicity
Beyond the preview
Go deeper on NCT02486198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486198.